Cover image for GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2025 Prime Therapeutics’...

Cover image for GLP-1 Pipeline Update: May 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-may-2025 Prime Therapeutics’ GLP-1...

Cover image for GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-august-2025 Prime Therapeutics’ GLP-1...

cover image GLP-1 Pipeline Update: November 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-november-2025 Prime Therapeutics’ GLP-1...

cover image GLP-1 Pipeline Update: Feb 2026 Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-february-2026 Prime Therapeutics’ GLP-1...

Cover image Quarterly view of the GLP-1 pipeline and anticipated indications. Prime Therapeutics /glp-1-pipeline-update-november-2024 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the...

cover image Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-may-2026 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the development...

Cover image Quarterly view of the GLP-1 pipeline and anticipated indications Prime Therapeutics /glp-1-pipeline-update-august-2026 Prime Therapeutics’ GLP-1 Pipeline Update focuses on the...

GLP-1 pipeline FAQs FDA-approved 2025 2027 Drug name/Manufacturer/Dosage form semaglutide 1.7 mg & 2.4 mg (Wegovy)/Novo Nordisk/SC DISCLAIMER The drug pipeline is fluid; the dates and information...

Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC tirzepatide (Zepbound)/Eli Lilly/SC T2DM Access the complete...

Drug name/Manufacturer/Dosage form orforglipron/Eli Lilly/oral retatrutide/Eli Lilly/SC T2DM Diabetic nephropathy (prevention in pts with T2DM & CKD) Alzheimers disease Are generic versions of...

2027 OSA + obesity/overweight 2028 Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC survodutide/Zealand & Boehringer Ingelheim/SC 2026 Drug name/Manufacturer/Dosage form...

Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC - FDA decision 4Q2025 tirzepatide (Zepbound)/Eli Lilly/SC - FDA submission withdrawn Drug name/Manufacturer/Dosage form...

T2DM 2026 Diabetic nephropathy (prevention in pts with T2DM & CKD) T1DM + obesity or overweight Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form...

Download our table OSA + obesity or overweight T2DM Drug name/Manufacturer/Dosage form dulaglutide (Trulicity)/Eli Lilly/SC liraglutide (Victoza)/Novo Nordisk/SC semaglutide 1 mg & 2 mg...

Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Besides Novo Nordisk and Eli Lilly, what other pharmaceutical companies have GLP1s in the pipeline in late-stage development?...

Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

Check out the most recent indications for these popular medications to treat a growing range of conditions